Navigation Links
OGT Announces Commercial and Financial Highlights for FY 2016
Date:11/22/2016

OXFORD, England, November 22, 2016 /PRNewswire/ --

 Highly integrated molecular genetics portfolio delivers significant revenue growth and sustainable profit 

Oxford Gene Technology (OGT), The Molecular Genetics Company has announced continued strong sales of its highly integrated molecular genetics product portfolio, delivering sustainable, profitable growth. Commercial and financial highlights for the year ended 30 September show the company delivering product sales of £18.4m, up 29% on FY 2015.

     (Logo: http://photos.prnewswire.com/prnh/20160909/406091LOGO)

  • Total revenue grew by 15% to £19.7m (FY2015: £17.1m)
  • Product revenues grew 29% to £18.4m (FY2015: £14.3m)
  • Fully integrated portfolio delivers sustainable profitable growth

OGT's impressive financial performance validates the company's strategy of developing innovative, high-growth products for molecular genetics. Dr Mike Evans, CEO of OGT, explained;

"The strategic decisions we have made over the last few years have reshaped the company to create a streamlined and profitable business that is fully focused on the development of innovative products for molecular genetics. Focussing on our integrated portfolio of molecular genetics products has driven strong sales growth and a significant increase in profits from commercial activities."

Commercial Highlights 

Cytocell®Fluorescence in situ hybridisation (FISH) probes for detecting gene rearrangements related to inherited genetic disease and cancer outstrip market growth

  • Continuing double-digit growth outstrips market growth; increased market share (market growth at 7%)
  • OGT maintains its position as a market-leading FISH provider with the widest range of FISH probes on the market
  • Further expansion of Cytocell FISH probe portfolio with more than 14 haematology probes and CE-IVD marked pathology probes for lung cancer and glial tumours added

CytoSure™: Broad range of array products for molecular cytogenetics, cancer and reproductive health research shows impressive growth and global new customer adoptions

  • Large increase in customer base thanks to successful exon-focused strategy including development of molecular arrays to complement NGS with gold-standard CNV detection
  • Continued successful market adoption of the CytoSure Constitutional v3 array, and launch of the CytoSure Constitutional v3 +LOH array - the only arrays incorporating the latest evidence-based content for enhanced detection of developmental disorders
  • CytoSure Affirm non-invasive pre-natal test (NIPT) nearing CE marking submission as UK approves use of NIPT as part of national screening programme

SureSeq™: Expanding portfolio of NGS library preparation products for the accurate detection of genetic variants sees increasing sales growth and a flexible customisation focus

  • Investment in new product development reflected by increasing sales growth and a strong sales pipeline
  • Launch of SureSeq myPanel™ NGS Custom Cancer Panels reinforcing the company's flexible customisation strategy - simplifying detection of important cancer gene variants
  • Expanding portfolio in both cancer and rare disease with new custom panel content and disease-focused panels near launch and in development

Looking forward to 2017, Dr Evans added, "Our business is now focused on sustainable, profitable growth and our strategy moving forward is to further target the growing molecular medicine market. As a part of this approach we will continue to develop and expand our popular customisation programmes - Cytocell myProbes®, SureSeq myPanel and customisable CytoSure array content - which enable us to be truly customer responsive and clearly sets OGT apart from the competition."

CytoSure™ and SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell®: Some products may not be available in your region.


'/>"/>
SOURCE Oxford Gene Technology (OGT)
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Viral Gene Announces Breakthrough in Colon Cancer: New Vaccine Targets Enzyme to Help Destroy Metastatic Tumor Cells
2. CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting
3. Neurotrope Announces Private Placement of $20 Million
4. ComplianceOnline Announces Seminar on Medical Device Risk Management
5. BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite
6. Symbios Announces Two National Institutes of Health SBIR Phase I Awards for Plasma Oxidation Technology
7. Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study
8. OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016
9. Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
10. Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction
11. Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2018)... ... August 31, 2018 , ... Rudina Thanasi, ... of a proprietary biofield energy treated nutraceutical supplement used in combating inflammation and ... response and blood, as well as, organ-specific inflammation. The reported data is as ...
(Date:8/31/2018)... (PRWEB) , ... August 30, 2018 , ... Small, wireless ... implants are slimming down and getting connected, too. Draper’s latest system is tiny in ... networked abilities. , A driving factor in the new implant design is the growing ...
(Date:8/29/2018)... LEXINGTON, Mass. (PRWEB) , ... August 28, 2018 , ... ... is announcing the full lineup of talks for NAVIGATE2018 . , Ryan ... NAVIGATE2018 , Cognition’s annual user conference. An experienced engineer and manager with Zimmer ...
(Date:8/29/2018)... (PRWEB) , ... August 28, 2018 , ... ... be presenting the results of a safety study performed on an allogeneic (donor ... American Veterinary Regenerative Medicine Association (NAVRMA) conference in September. He is also ...
Breaking Biology Technology:
(Date:8/31/2018)... ... August 30, 2018 , ... In recent years ... of drug discovery programs. Longer-target engagement can result in improved efficacy and reduced ... expensive instrumentation, or require the alteration of the molecules involved. The limitations of ...
(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder ... recognizes women of excellence in the field of intellectual property, and named Daniela ... Women in IP Award aims to encourage and support women in their pursuit ...
(Date:8/26/2018)... ... August 24, 2018 , ... ... diagnostic laboratories. However, this technology introduces many well-described challenges around data processing, ... the South London NHS Genomic Medicine Centre. The Viapath Genetics Laboratories have ...
Breaking Biology News(10 mins):